Randall J Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology

Phone314-286-1967

Fax314-747-7060

Emailbatemanr@neuro.wustl.edu

Board Certifications

  • Neurology

Related Links

Recognition

  • Chancellor’s Award for Innovation and Entrepreneurship, Washington University, 2013
  • MetLife Promising Investigator Award, 2012
  • American Society for Clinical Investigation Council, 2012
  • Alzheimer’s Association Zenith Fellows Award, 2011
  • Alzheimer Research Forum Open Innovation Award, 2011
  • American Neurological Associate Membership, 2011
  • Glenn Award for Research in Biological Mechanisms of Aging, 2011
  • Co-Recipient, Health Care Heroes in Innovation by the St. Louis Business Journal, 2010
  • St. Louis Academy of Science Innovator of the Year Award, 2009
  • Kopolow Award, 2007
  • World Technology Award Nominee for Health and Medicine Associate, 2006
  • Scientific American 50, award for outstanding technological leadership, one of the top 50 scientific advancements, 2006
  • American Neurological Association Plenary Session Speaker, 2005
  • AAN Platform Presentation and Travel Fellowship Award, 2005
  • AAN Foundation Corporate Roundtable Clinical Research Training Fellowship, 2004
  • Undergraduate Research Fellowship, Howard Hughes Medical Institute, 1994

Publications

  • Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One. 2014 Mar 19;9(3):e89998.
  • Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM; Dominantly Inherited Alzheimer Network. Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease. Sci Transl Med. 2014 Mar 5;6(226):226ra30.
  • Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9.
  • Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, Morris JC. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther. 2013 Oct 17;5(5):48. [Epub ahead of print]
  • Cash DM, Ridgway GR, Liang Y, Ryan NS, Kinnunen KM, Yeatman T, Malone IB, Benzinger TL, Jack CR Jr, Thompson PM, Ghetti BF, Saykin AJ, Masters CL, Ringman JM, Salloway SP, Schofield PR, Sperling RA, Cairns NJ, Marcus DS, Xiong C, Bateman RJ, Morris JC, Rossor MN, Ourselin S, Fox NC; Dominantly Inherited Alzheimer Network (DIAN). The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology. 2013 Oct 15;81(16):1425-33.
  • Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct;169(10):737-43.
  • Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ. Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics. Anal Biochem. 2013 Sep 1;440(1):56-62.
  • Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013 Jun 12;5(189):189ra77.
  • Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013 Jan;73(1):104-19.
  • Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M, Budd SL, Bateman RJ. β-Amyloid Dynamics in Human Plasma. Arch Neurol. 2012 Dec;69(12):1591-7.
  • Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 1;2(10):975-984.
  • Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer’s disease pathology. Sci Transl Med. 2012 Sep 5;4(150):150ra122.
  • Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012 Aug 30;367(9):795-804.
  • Bateman RJ, Boychuk CR, Philbin KE, Mendelowitz D. β adrenergic receptor modulation of neurotransmission to cardiac vagal neurons in the nucleus ambiguus. Neuroscience. 2012 May 17;210:58-66.
  • Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, Holtzman DM, Bateman RJ. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One. 2012;7(6):e38013.

Randall J. Bateman, M.D. is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine.

Dr. Bateman’s laboratory investigates the causes, and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques from basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers for Alzheimer’s disease. Dr. Bateman’s lab measures the pathophysiology of Alzheimer’s disease in humans and measures amyloid-beta isoform kinetics in Alzheimer’s disease. Dr. Bateman trains postdoctoral fellows, graduate students, and undergraduates in his lab.

Dr. Bateman led the development of a technique known as stable isotope-linked kinetics (SILK) that made it possible to determine that clearance of amyloid beta is impaired in patients with Alzheimer’s disease. Bateman and his colleagues are now studying whether alterations in amyloid beta clearance levels can be used to predict Alzheimer’s disease years before symptoms become apparent. Their goal is to prevent damage and loss of brain cells by intervening early in the disease process.
Dr. Bateman is the Director of the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) which is launching the first clinical trials in autosomal dominant Alzheimer’s disease (ADAD) aiming to prevent the onset of memory impairment and dementia. Dr. Bateman led efforts to form the first pharma consortium focused on ADAD, the DIAN Pharma Consortium (a collaboration of 10 pharmaceutical companies), and was granted the “largest-ever” Alzheimer’s Association research grant for the DIAN-TU. In 2010, he organized the Autosomal Dominant Alzheimer’s Disease Forum, a patient and family advocacy group for individuals affected by ADAD. Dr. Bateman also serves as the Associate Director and Clinical Core Leader of the DIAN, an international collaboration of leading research centers dedicated to studying ADAD.

Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University. He is also an investigator for the Charles F. and Joanne Knight Alzheimer’s Disease Research Center and for the Hope Center for Neurological Disorders. He is an inventor of several pending patents and an issued patent, and the scientific co-founding member of C2N Diagnostics, a biotechnology company located at the Center for Emerging Technology in St. Louis.

Dr. Bateman’s honors include the AAN Foundation Corporate Roundtable Clinical Research Fellowship, an American Neurological Association Plenary Session Speaker, a World Technology Award Nominee for Health and Medicine Associate, Scientific American 50 Award recognizing the top 50 scientific achievements of 2006, the Kopolow Award, the 2007 Alzheimer’s Research Forum Community Award, the Beeson Award, the St. Louis Academy of Science Innovator of the Year award, the Co-recipient of the Health Care Heroes in Innovation by the St. Louis Business Journal, the Glenn Award for Research, the 2011 Alzheimer’s Association Zenith Fellows Award, the 2011 Alzheimer’s Research Forum Open Innovation Award, the 2012 MetLife Promising Investigator Award.

His membership in honorary societies includes the American Neurological Association and the American Society for Clinical Investigation Council. Dr. Bateman’s professional memberships include the American Academy of Neurology and the Society for Neuroscience. He serves as an editor and reviewer for many prominent scientific journals and is a sought-after lecturer nationally and internationally.